{"prompt": "['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 46 of 129', 'The following actions must be taken if a subject fails to return to the trial site for a required', 'visit:', 'The trial site must attempt to contact the subject and reschedule the missed', 'visit as soon as possible and counsel the subject on the importance of', 'maintaining the assigned visit schedule and ascertain whether the subject', 'wishes to and/or should continue in the trial.', 'Before a subject is deemed lost to follow-up, the investigator or designee must', 'make every effort to regain contact with the subject (where possible,', \"3 telephone calls and, if necessary, a certified letter to the subject's last known\", 'mailing address or local equivalent methods). These contact attempts should be', \"documented in the subject's medical record.\", 'Should the subject continue to be unreachable, they will be considered to have', 'withdrawn from the trial with a primary reason of lost to follow-up.', 'TMF-000005673 - Version 4.0']['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 47 of 129', '9 Treatments', '9.1 Trial product description', '9.1.1 Investigational medicinal product', 'Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that', 'specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is', 'presented as a liquid formulation for SC administration.', 'Tralokinumab and placebo will be packaged in individually numbered kits, each containing', '1 pre-filled syringe. Refer to Panel 5 for further details.', 'Panel 5 Identification of investigational medicinal products', 'Investigational', 'Dosage form', 'Concentration and', 'Manufacturer', 'medicinal', 'formulation', 'product', 'Tralokinumab', '150 mg/mL solution', 'Formulated at a nominal', 'MedImmune', 'for injection in an', 'concentration of 150 mg/mL in', 'accessorised', '50 mM sodium acetate/acetic', 'pre-filled syringe,', 'acid buffer, 85 mM sodium', '1.0 mL fill volume.', 'chloride, 0.01% (w/v) PS-80,', 'pH 5.5 solution.', 'Placebo', 'Placebo solution for', 'Placebo contains the same', 'MedImmune', 'injection in an', 'excipients, in the same', 'accessorised', 'concentration only lacking', 'pre-filled syringe,', 'tralokinumab.', '1.0 mL fill volume.', 'The accessorised pre-filled syringe is a single-use, disposable system that is designed to', 'administer the labelled dose of the system to the subcutaneous space during 1 injection and', 'automatically provide a safety mechanism to reduce the occurrence of accidental needle sticks', 'during disposal of the system.', 'The accessorised pre-filled syringe consists of a pre-filled syringe sub-assembly (1 mL', 'pre-filled syringe barrel with a 1/2 inch 27 gauge thin wall staked-in needle, rigid needle', 'shield, plunger stopper), and a safety device.', 'TMF-000005673 - Version 4.0']['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 48 of 129', '9.1.2 Non-investigational medicinal product', 'Each subject will be prescribed a non-investigational medicinal product (NIMP) for the', 'duration of the trial: the subjects will receive a TCS cream (Europe: Class 3 [potent];', 'US: Class 4 [mid-strength]) from randomisation (Week 0) to Week 32. This will be provided', 'as mometasone furoate, 0.1% cream in kit sizes of 180-225 g every 2 weeks. This should be', 'the only TCS product applied to the body during this period, excluding areas of the body', 'where the supplied TCS is not advisable or where continued use is considered unsafe (see', 'Section 9.1.3.2 for further details).', '9.1.3 Administration of trial products', '9.1.3.1 Administration of IMP', 'The IWRS will assign the required IMP kit numbers for each subject at each dispensing visit.', 'The first day of dosing is considered Day 0 (visit 3). Each subject will receive 4 SC injections', '(each 1.0 mL) of 150 mg tralokinumab or placebo to receive a total loading dose of', '600 mg tralokinumab or placebo.', 'At subsequent visits in the initial treatment period, each subject will receive 2 SC injections', '(each 1.0 mL) of 150 mg tralokinumab or placebo to receive a total dose of 300 mg', 'tralokinumab or placebo (Q2W).', 'Subjects in the continuation treatment period will receive either:', 'Tralokinumab Q2W (2 SC injections [each 1.0 mL] of 150 mg tralokinumab).', 'Tralokinumab Q4W (alternating dose administrations of 2 SC injections [each', '1.0 mL] of 150 mg tralokinumab and placebo).', 'Placebo Q2W (2 SC injections [each 1.0 mL] of placebo)', 'Dosing visits are shown in the schedule of procedures (Section 4). The last administration of', 'IMP will occur at Week 30.', 'IMP will be administered by a qualified, unblinded healthcare professional (HCP;', 'see', 'Section 9.2.1 for blinding details). A minimum interval of 7 days is required between 2 dosing', 'visits.', 'TMF-000005673 - Version 4.0']\n\n###\n\n", "completion": "END"}